Multicentre trial of a programmable implantable insulin pump in type I diabetes

M. Pinget, N. Jeandidier, F. Ortega, D. Wix, J. Margetaux, C. Feinbock, J. Diglas, H. Mendl, K. Irsigler, M. Scavini, G. Petrella, M. Torri, M. Cristallo, G. Pozza, H. J. Luddeke, T. Groth, R. Renner, K. D. Hepp, J. L. Selam

Research output: Contribution to journalArticlepeer-review


Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10-30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.

Original languageEnglish
Pages (from-to)322-325
Number of pages4
JournalInternational Journal of Artificial Organs
Issue number6
Publication statusPublished - 1995


  • implantable devices
  • intensive insulin therapy
  • intraperitoneal insulin delivery

ASJC Scopus subject areas

  • Biophysics


Dive into the research topics of 'Multicentre trial of a programmable implantable insulin pump in type I diabetes'. Together they form a unique fingerprint.

Cite this